LRRK2 and Parkinson disease: In this context, a significant reduction in α-syn-mediated neuroinflammation, with attenuated microglial activation and T cell infiltration, in the adeno-associated viral (AAV) vector-based PD model treated with LRRK2 kinase inhibitor MLi2 has been shown [29].